logoCabeceraNinos

Hemos leído sobre ... Tratamientos

Última actualización: 17 enero 2017


DICIEMBRE 2016
  • Lakhanpal A, Brahn E.
    Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions.
    Clin Rheumatol. 2016 Dec;35(12):2869-2875.
    https://www.ncbi.nlm.nih.gov/pubmed/27714482
  • Windschall D, Horneff G.
    Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
    Clin Rheumatol. 2016 Dec;35(12):2925-2931.
    https://www.ncbi.nlm.nih.gov/pubmed/27709443 
  • Verazza S, Davì S, Consolaro A, Bovis F, Insalaco A, Magni-Manzoni S, Nicolai R, Marafon DP, De Benedetti F, Gerloni V, Pontikaki I, Rovelli F, Cimaz R, Marino A, Zulian F, Martini G, Pastore S, Sandrin C, Corona F, Torcoletti M, Conti G, Fede C, Barone P, Cattalini M, Cortis E, Breda L, Olivieri AN, Civino A, Podda R, Rigante D, La Torre F, D'Angelo G, Jorini M, Gallizzi R, Maggio MC, Consolini R, De Fanti A, Muratore V, Alpigiani MG, Ruperto N, Martini A, Ravelli A; Italian Pediatric Rheumatology Study Group.
    Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept.
    Pediatr Rheumatol Online J. 2016 Dec 20;14(1):68.
    https://www.ncbi.nlm.nih.gov/pubmed/27993144

NOVIEMBRE 2016
  • Harrington J, Holmyard D, Silverman E, Sochett E, Grynpas M.
    Bone histomorphometric changes in children with rheumatic disorders on chronic glucocorticoids.
    Pediatr Rheumatol Online J. 2016 Nov 10;14(1):58.
    https://www.ncbi.nlm.nih.gov/pubmed/27832795

OCTUBRE 2016
  • McDonagh JE, Shaw KL, Prescott J, Smith FJ, Roberts R, Gray NJ.
    "Sometimes I feel like a pharmacist": identity and medication use among adolescents with juvenile arthritis.
    Pediatr Rheumatol Online J. 2016 Oct 19;14(1):57.
    https://www.ncbi.nlm.nih.gov/pubmed/27756328

AGOSTO 2016

JULIO 2016
  • Davies HD; COMMITTEE ON INFECTIOUS DISEASES.
    Infectious Complications With the Use of Biologic Response Modifiers in Infants and Children.
    Pediatrics. 2016 Aug;138(2). pii: e20161209. doi: 10.1542/peds.2016-1209. Epub 2016 Jul 18.
    http://www.ncbi.nlm.nih.gov/pubmed/27432853
  • Orrock JE, Ilowite NT.
    Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
    Expert Rev Clin Pharmacol. 2016 Aug;9(8):1015-24. doi: 10.1080/17512433.2016.1204910. Epub 2016 Jul 6.
    http://www.ncbi.nlm.nih.gov/pubmed/27367267

JUNIO 2016
  • Fráňová J, Fingerhutová Š, Kobrová K, Srp R, Němcová D, Hoza J, Uher M, Saifridová M, Linková L, Doležalová P.
    Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration.
    Pediatr Rheumatol Online J. 2016 Jun 14;14(1):36. doi: 10.1186/s12969-016-0099-z
    http://www.ncbi.nlm.nih.gov/pubmed/27301536
  • Sterba Y, Ilowite N.
    Biologics in Pediatric Rheumatology: Quo Vadis?
    Curr Rheumatol Rep. 2016 Jul;18(7):45. doi: 10.1007/s11926-016-0593-9
    http://www.ncbi.nlm.nih.gov/pubmed/27306623

MAYO 2016

ABRIL 2016

MARZO 2016

FEBRERO 2016
  • Nguyen TA, Celano NJ, Matiz C.
    Palisaded Neutrophilic Granulomatous Dermatitis in a Child with Juvenile Idiopathic Arthritis on Etanercept.
    Pediatr Dermatol. 2016 Mar;33(2):e156-7. doi: 10.1111/pde.12797. Epub 2016 Feb 10.
    http://www.ncbi.nlm.nih.gov/pubmed/26860064
  • Taddio A, Cattalini M, Simonini G, Cimaz R.
    Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.
    Expert Rev Clin Immunol. 2016 Feb 19:1-9. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26809126
  • Lopalco G, Rigante D, Giannini M, Galeazzi M, Lapadula G, Iannone F, Cantarini L.
    Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders.
    Clin Exp Rheumatol. 2016 Feb 26. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26940286

DICIEMBRE 2015

  • Calzada-Hernández J, Anton-López J, Bou-Torrent R, Iglesias-Jiménez E, Ricart-Campos S, Martín de Carpi J; Carmen García de Vicuña Muñoz de la Nava, Torrente-Segarra V, Sánchez-Manubens J, Giménez-Roca C, Rozas-Quesada L, Juncosa-Morros MT, Fortuny C, Noguera-Julian A.
    Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.

    Pediatr Rheumatol Online J. 2015 Dec 3;13(1):54. doi: 10.1186/s12969-015-0054-4.
    http://www.ncbi.nlm.nih.gov/pubmed/26635208
  • Vaz JL, Fernandes V, Nogueira F, Arnóbio A, Levy RA.
    Infliximab-induced autoantibodies: a multicenter study.
    Clin Rheumatol. 2015 Dec 17.
    http://www.ncbi.nlm.nih.gov/pubmed/26676808
  • Hügle B, Horneff G.
    The Role of Synthetic Drugs in the Biologic Era: Therapeutic Strategies for Treating Juvenile Idiopathic Arthritis.

    Expert Opin Pharmacother. 2015 Dec 17.
    http://www.ncbi.nlm.nih.gov/pubmed/26678914

NOVIEMBRE 2015

  • Agapitos Patakas, Rui-Ru Ji, William Weir, Sean E. Connolly, Robert A. Benson, Steven G. Nadler, James M Brewer, Iain B McInnes and Paul Garside
    Abatacept inhibits T cell priming by inducing of a unique transcriptional profile that reduces their ability to activate antigen presenting cells
    Arthritis & Rheumatology
    DOI: 10.1002/art.39470
    Abstract
  • Doyt L. Conn
    Is the Availability of Delayed Release Prednisone an Important Clinical Advance?
    Arthritis Care & Research
    DOI: 10.1002/acr.22745
    Abstract
  • Matthew Laurence Stoll, Yoginder Nath Vaid, Saurabh Guleria, Timothy Beukelman, Peter Daniel Waite, and Randy Quentin Cron
    Magnetic Resonance Imaging Findings following Intraarticular Infliximab Therapy for Refractory Temporomandibular Joint Arthritis among Children with Juvenile Idiopathic Arthritis

    J Rheumatol November 2015 42(11):2155-2159; doi:10.3899/jrheum.150308
    Abstract
  • Anna Felis-Giemza and Robert J. Moots
    Measurement of anti-drug antibodies to biologic drugs

    Rheumatology (2015) 54 (11): 1941-1943 doi:10.1093/rheumatology/kev279
    Extract
  • Tania S. Amin, Sian Shenton, Kathleen Mulligan, Lucy R. Wedderburn, Mark Wood, Vanessa VanRooyen, and Valentina Leone
    Strategies for the prevention and management of methotrexate-related nausea and vomiting in juvenile idiopathic arthritis: results of a UK Paediatric Rheumatology prescriber survey
    Rheumatology (2015) 54 (11): 2108-2109 doi:10.1093/rheumatology/kev259
    Extract

OCTUBRE 2015
  • Hawwa AF, AlBawab A, Rooney M, Wedderburn LR, Beresford MW, McElnay JC.
    Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study
    Arthritis Res Ther. 2015 Oct 22;17(1):295.
    http://www.ncbi.nlm.nih.gov/pubmed/26493320
  • Horneff G.
    Biologic-Associated Infections in Pediatric Rheumatology
    Curr Rheumatol Rep. 2015 Nov;17(11):66. doi: 10.1007/s11926-015-0542-z.
    http://www.ncbi.nlm.nih.gov/pubmed/26385753 
  • Ding HJ, Denniston AK, Rao VK, Gordon C.
    Hydroxychloroquine-related retinal toxicity
    Rheumatology (Oxford). 2015 Oct 1. pii: kev357. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26428520

AGOSTO 2015
  • Rondeau JM, Ramage P, Zurini M, Gram H.
    The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.
    MAbs. 2015 Aug 18:0. EPUB ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26284424

JULIO 2015
  • Horneff G
    Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.
    Expert Opin Drug Saf. 2015 Jul;14(7):1111-26. doi: 10.1517/14740338.2015.1042453.
    http://www.ncbi.nlm.nih.gov/pubmed/26084637

JUNIO 2015
  • Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH.
    Rituximab for IgG4-related disease: a prospective, open-label trial.
    Ann Rheum Dis. 2015 Jun;74(6):1171-7. doi: 10.1136/annrheumdis-2014-206605.
    http://www.ncbi.nlm.nih.gov/pubmed/25667206
  •  Mercer LK, Lunt M, Low AL, Dixon WG, Watson KD, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium.
    Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Ann Rheum Dis. 2015 Jun;74(6):1087-93. doi: 10.1136/annrheumdis-2013-204851.
    http://www.ncbi.nlm.nih.gov/pubmed/24685910
  •  Scheinberg M.
    Therapy: Facing up to biosimilar agents-the ACR position.
    Nat Rev Rheumatol. 2015 Jun;11(6):322-4. doi: 10.1038/nrrheum.2015.57.
    http://www.ncbi.nlm.nih.gov/pubmed/25907701

MAYO 2015
    • Hermine I Brunner, Nicolino Ruperto, Zbigniew Zuber, Caroline Keane, Olivier Harari, Andrew Kenwright, et al for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)
      Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
      Ann Rheum Dis. 2015;74:1110-1117 doi:10.1136/annrheumdis-2014-205351
      http://ard.bmj.com/content/74/6/1110.abstract

ABRIL 2015
  • Bulatović Ćalasan M, Vastert SJ, Scholman RC, Verweij F, Klein M, Wulffraat NM, Prakken BJ, van Wijk F.
    Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis
    Rheumatology (Oxford). 2015 Apr 14. pii: kev101. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/25877908

MARZO 2015
    • Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, Touitou I, Koné-Paut I; MAIL1 (Maladies Auto-inflammatoires et Anti-IL-1) study Group on the behalf of CRI (Club Rhumatisme et Inflammation).
      Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
      Orphanet J Rare Dis. 2015 Feb 15;10(1):19. [Epub ahead of print]
      http://www.ncbi.nlm.nih.gov/pubmed/25758134
    • Ungprasert P, Srivali N, Wijarnpreecha K, Charoenpong P, Knight EL.
      Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and meta-analysis
      Rheumatology (2015) 54 (4): 736-742. doi:10.1093/rheumatology/keu408
      http://rheumatology.oxfordjournals.org/content/54/4/736.abstract
    • Strand V, Burmester GR, Zerbini CAF, Mebus CA, Zwillich SH, Gruben D, Wallenstein GV.
      Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial
      Arthritis Care Res (Hoboken) 2015; 67(4):475-483. DOI: 10.1002/acr.22453
      http://onlinelibrary.wiley.com/doi/10.1002/acr.22453/epdf
    • Séïté JF, Hillion S, Harbonnier T, Pers JO.
      Review: intravenous immunoglobulin and B cells: when the product regulates the producer.
      Arthritis Rheumatol. 2015 Mar;67(3):595-603. doi: 10.1002/art.38910
      http://www.ncbi.nlm.nih.gov/pubmed/25303681

DICIEMBRE 2014
  • Burnett HF, Ungar WJ, Regier DA, Feldman BM, Miller FA.
    Parents' willingness to pay for biologic treatments in juvenile idiopathic arthritis.
    Value Health. 2014 Dec;17(8):830-7. doi: 10.1016/j.jval.2014.08.2668. Epub 2014 Nov 6.
    http://www.ncbi.nlm.nih.gov/pubmed/25498778
    Präger TM, Meyer P, Rafayelyan S, Minden K, Jost-Brinkmann PG.
    Effect of methotrexate on the mandibular development of arthritic rabbits.
    Eur J Orthod. 2014 Dec 17. pii: cju070. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/25518996
  • Shimizu M, Hamaguchi Y, Ishikawa S, Ueno K, Yachie A.
    Successful treatment with tocilizumab of a psoriasiform skin lesion induced by etanercept in a patient with juvenile idiopathic arthritis.
    Mod Rheumatol. 2014 Dec 15:1-2.
    http://www.ncbi.nlm.nih.gov/pubmed/25496406
  • Berard RA, Laxer RM.
    Early aggressive therapy for patients with juvenile idiopathic arthritis: are we there yet?
    J Rheumatol. 2014 Dec;41(12):2343-6.
    http://www.ncbi.nlm.nih.gov/pubmed/25452178

NOVIEMBRE 2014

OCTUBRE 2014
  • Ringold S, Hendrickson A, Abramson L, Beukelman T, Blier PR, Bohnsack J, Chalom EC, Gewanter HL, Gottlieb B, Hollister R, Hsu J, Hudgins A, Ilowite NT, Klein-Gitelman M, Lindsley C, LopezBenitez JM, Lovell DJ, Mason T, Milojevic D, Moorthy LN, Nanda K, Onel K, Prahalad S, Rabinovich CE, Ray L, Rouster-Stevens K, Ruth N, Shishov M, Spalding S, Syed R, Stoll M, Vehe RK, Weiss JE, White AJ, Wallace CA, Sobel RE.
    A novel method to collect medication adverse events in juvenile arthritis: Results from the Childhood Arthritis and rheumatology research alliance enhanced drug safety surveillance project (EDSSP).
    Arthritis Care Res (Hoboken). 2014 Oct 20. doi: 10.1002/acr.22487. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/25331530 
  • Windschall D, Müller T, Becker I, Horneff G.
    Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.
    Rheumatol Int. 2014 Sep 11. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/25208527 
  • Schmeling H, Horneff G, Benseler SM, Fritzler MJ.
    Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?
    Nat Rev Rheumatol. 2014 Nov;10(11):682-690. doi: 10.1038/nrrheum.2014.140. Epub 2014 Aug 12. Review.
    http://www.ncbi.nlm.nih.gov/pubmed/25112604 
  • Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G.
    Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Arthritis Rheumatol. 2014 Sep;66(9):2580-9. doi: 10.1002/art.38741.
    http://www.ncbi.nlm.nih.gov/pubmed/24942886 
  • K A van Schie, M H Hart, E R de Groot, S Kruithof, L A Aarden, G J Wolbink, T Rispens
    Concise report: The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region
    Ann Rheum Dis Published Online First: 23 October 2014
    doi:10.1136/annrheumdis-2014-206237
    http://ard.bmj.com/content/early/2014/10/23/annrheumdis-2014-206237.abstract

SEPTIEMBRE 2014

AGOSTO 2014
  • Mannion ML, Xie F, Curtis JR, Beukelman T.
    Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of Tumor Necrosis Factor Inhibitors.
    J Rheumatol. 2014 Aug 1.
    http://www.ncbi.nlm.nih.gov/pubmed/25086081

JULIO 2014
  • Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, Muscal E, Deiva K, Andersen E, Eyre MR, Eleftheriou D, Brogan PA, Kneen R, Alper G, Anlar B, Wassmer E, Heineman K, Hemingway C, Riney CJ, Kornberg A, Tardieu M, Stocco A, Banwell B, Gorman MP, Benseler SM, Lim M.
    Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.
    Neurology. 2014 Jul 8;83(2):142-50
    http://www.ncbi.nlm.nih.gov/pubmed/24920861
  • Scott LJ.
    Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases.
    Drugs. 2014 Jul 18. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/25034360
  • Dale RC1, Brilot F2, Duffy LV2, Twilt M2, Waldman AT2, Narula S2, Muscal E2, Deiva K2, Andersen E2, Eyre MR2, Eleftheriou D2, Brogan PA2, Kneen R2, Alper G2, Anlar B2, Wassmer E2, Heineman K2, Hemingway C2, Riney CJ2, Kornberg A2, Tardieu M2, Stocco A2, Banwell B2, Gorman MP2, Benseler SM2, Lim M2.
    Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.
    Neurology. 2014 Jul 8;83(2):142-50. 
    http://www.ncbi.nlm.nih.gov/pubmed/24920861
  • [No authors listed]
    Discrepancy Between Clinical and Radiological Responses to Tocilizumab Treatment in Patients with Systemic-onset Juvenile Idiopathic Arthritis.
    J Rheumatol. 2014 Jul;41(7):1567.
    http://www.ncbi.nlm.nih.gov/pubmed/24986971
  • Windschall D1, Müller T, Becker I, Horneff G.
    Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-relatedarthritis and psoriasis arthritis.
    Clin Rheumatol. 2014 Jul 18.
    http://www.ncbi.nlm.nih.gov/pubmed/25034081
  • Sobel RE1, Lovell DJ2, Brunner HI2, Weiss JE3, Morris PW4, Gottlieb BS5, Chalom EC6, Jung LK7, Onel KB8, Petiniot L9, Goldsmith DP10, Nanda K11, Shishov M12, Abramsky S1, Young JP13, Giannini EH2.
    Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry.
    Pediatr Rheumatol Online J. 2014 Jul 16;12:29.
    http://www.ncbi.nlm.nih.gov/pubmed/25034081
  • Shimizu M1, Ueno K2, Ishikawa S2, Tokuhisa Y2, Inoue N2, Yachie A2.
    Treatment of refractory polyarticular juvenile idiopathic arthritis with tacrolimus.
    Rheumatology (Oxford). 2014 Jul 26.
    http://www.ncbi.nlm.nih.gov/pubmed/25065006
  • Autmizguine J1, Cohen-Wolkowiez M, Ilowite N; for the RAPPORT investigators.
    Rilonacept Pharmacokinetics in Children With Systemic Juvenile Idiopathic Arthritis.
    J Clin Pharmacol. 2014 Jul 30.
    http://www.ncbi.nlm.nih.gov/pubmed/25079592

MAYO 2014
  • Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, Schroeder S, Lauener R, Saurenmann RK.
    Infliximab in Pediatric Rheumatology Patients: A Retrospective Analysis of Infusion Reactions and Severe Adverse Events During 2246 Infusions over 12 Years.
    J Rheumatol. 2014 May 15. pii: jrheum.131231. [Epub ahead of print]
  • Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, Schroeder S, Lauener R, Saurenmann RK.
    Infliximab in Pediatric Rheumatology Patients: A Retrospective Analysis of Infusion Reactions and Severe Adverse Events During 2246 Infusions over 12 Years.
    J Rheumatol. 2014 May 15. pii: jrheum.131231. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/24833759

MARZO 2014
  • Santer M, Ring N, Yardley L, Geraghty AW, Wyke S.
    Treatment non-adherence in pediatric long-term medical conditions: systematic review and synthesis of qualitative studies of caregivers' views.
    BMC Pediatr. 2014 Mar 4;14(1):63. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/24593304
  • Tanaka T, Narazaki M, Ogata A, Kishimoto T.
    A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
    Semin Immunol. 2014 Mar 1. pii: S1044-5323(14)00010-4. doi: 10.1016/j.smim.2014.01.009. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/24594001

FEBRERO 2014
  • Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H.
    Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years.
    Clin Rheumatol. 2014 Feb 2. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/24487484
  • Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H.
    The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.
    Rheumatology (Oxford). 2014 Feb;53(2):213-22. doi: 10.1093/rheumatology/ket260. Epub 2013 Aug 14.
    http://www.ncbi.nlm.nih.gov/pubmed/23946436
  • Iannone F, La Montagna G, Bagnato G, Gremese E, Giardina A, Lapadula G.
    Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial.
    J Rheumatol. 2014 Feb;41(2):286-92. doi: 10.3899/jrheum.130658. Epub 2014 Jan 15.
    http://www.ncbi.nlm.nih.gov/pubmed/24429167
  • Hashkes PJ, Becker ML, Cabral DA, Laxer RM, Paller AS, Rabinovich CE, Turner D, Zulian F.
    Methotrexate: new uses for an old drug.
    J Pediatr. 2014 Feb;164(2):231-6. doi: 10.1016/j.jpeds.2013.10.029.
    http://www.ncbi.nlm.nih.gov/pubmed/24286573

NOVIEMBRE 2013

OCTUBRE 2013
  • Frampton JE.
    Tocilizumab: A Review of Its Use in the Treatment of Juvenile Idiopathic Arthritis.
    Paediatr Drugs. 2013 Oct 24. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/24155139
  • Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, Ilowite NT, Winsor J, Fox K, Natter M, Sundy JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S,Jahreis A, Meeker-O'Connell A, Mittleman BB, Murphy BM, Peterson ED, Raymond SC, Setoguchi S, Siegel JN, Sobel RE, Solomon D, Southwood TR, Vesely R, White PH, Wulffraat NM, Sandborg CI.
    Using Registries to Identify Adverse Events in Rheumatic Diseases.
    Pediatrics.2013 Oct 21. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/24144710
  • Prince FH, Solomon DH.
    Dosing of biologics in juvenile idiopathic arthritis: is the sky the limit?
    J Rheumatol. 2013 Oct;40(10):1643-5. doi: 10.3899/jrheum.130875.
    http://www.ncbi.nlm.nih.gov/pubmed/2408575

SEPTIEMBRE 2013
  • Ioannidis JP, Karassa FB, Druyts E, Thorlund K, Mills EJ
    Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales.
    Nat Rev Rheumatol 2013 Sep 3. doi: 10.1038/nrrheum.2013.134. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/23999553

MAYO 2013
PATROCINADORES

Área de Socios